Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Continuous positive airway pressure (CPAP) offers a valid non-invasive respiratory support for patients with Coronavirus Disease 2019 (COVID-19) pneumonia [1]. CPAP treatment isn’t free from complications such as pneumothorax/pneumomediastinum, hemodynamic instability, or delirium and requires careful monitoring [1, 2]. Accordingly, timely CPAP removal appears desirable [1, 2]. Our aim was to identify weaning predictors and assess their performance in COVID-19 patients treated with helmet CPAP.
A prospective, observational, cohort study was conducted in our high dependency respiratory unit including consecutive adult patients with laboratory confirmed COVID-19 pneumonia that underwent a weaning trial from CPAP between March 2020 and February 2021 (training cohort).
Anzeige
Patients’ readiness to undergo a weaning trial was judged by the treating physician. A weaning trial was the reduction in support to minimal positive end-expiratory pressure (PEEP≈2 cmH2O, including antiviral filters) maintaining a FiO2 ≤ 60% [1, 2]. Absence of respiratory distress and SpO2 ≥ 94% in the subsequent 30 min lead to helmet removal and oxygen supplementation with FiO2 ≤ 60%. A weaning failure was the need to restore CPAP because of respiratory distress or SpO2 ≤ 94% in any moment beginning from the low PEEP trial and during the subsequent 12 h.
Weaning predictors were assessed before reducing PEEP, and included: (1) ROX index (SpO2/FiO2/respiratory rate (RR)) [3], (2) modified ROX index (partial pressure of oxygen (PaO2) to FiO2 ratio/RR—mROX) [3], (3) alveolar-arterial (A-a) O2 gradient, (4) Sequential Organ Failure Assessment (SOFA) score [4].
Sensitivity and specificity for different thresholds and the area under the receiver operating characteristic curve (AUROC) was calculated for all indexes. The index that best performed in the training cohort was tested in a validation cohort of patients hospitalized in two general wards of our institution. Statistical significance was a p value ≤ 0.05. Analyses were performed with IBM SPSS Statistics V.23.0 (Armonk, NY). The study (NCT04307459) was approved by the local ethical committee (17263/2020) and all patients gave written informed consent.
Seventy-four patients formed the training cohort: 61 (82.5%) succeeded and 13 (17.5%) failed the weaning trial (Table 1). At weaning trial, patients that failed had higher SOFA score, A-a O2 and RR, while PaO2/FiO2, ROX and mROX were higher in patients that succeeded weaning (Table 1). The mROX index had the best AUROC (0.830) and the value that best discriminated weaning success from failure was 8.4 mmHg/bpm (sensitivity 0.80, specificity 0.77) (Fig. 1). This threshold was tested in the validation cohort (44 patients; median age 65, 82% males) of which 32 (72.7%) succeeded and 12 (27.3%) failed weaning. The two cohorts were comparable in terms of clinical characteristics and CPAP duration before weaning. AUROC for mROX in the validation cohort was 0.828, sensitivity and positive predictive value 0.88, specificity and negative predictive value 0.67. Patients with mROX ≥ 8.4 after 5 days of CPAP had twice the probability to be free from CPAP compared with patients with mROX < 8.4 (Fig. 1).
Table 1
Clinical characteristics at admission and at weaning trial in patients that succeeded and failed CPAP weaning
Characteristics
Weaning success (n = 61)
Weaning failure (n = 13)
p valuea
Age, years
62 (12)
74 (8)
0.001
Males, n (%)
43 (70)
8 (61)
0.526
Hypertension, n (%)
30 (49)
7 (54)
0.760
Diabetes mellitus, n (%)
13 (21)
3 (23)
0.999
Ischemic heart disease, n (%)
6 (10)
4 (31)
0.067
Obesity, n (%)
26 (43)
6 (46)
0.816
Respiratory disease, n (%)
10 (16)
0 (0)
0.116
CPAP days at weaning trial
4 (2–6)
4 (2.5–5)
0.854
In-Hospital treatments
Antibiotics, n (%)
50 (82.0%)
9 (69.2%)
0.446
LMWH prophylactic, n (%)
39 (63.9%)
8 (61.5%)
0.999
LMWH therapeutic, n (%)
30 (49.2%)
9 (69.2%)
0.189
Systemic corticosteroids, n (%)
46 (75.4%)
9 (69.2%)
0.729
Clinical status at admission
Lymphocytes, × 106/L
900 (600–1400)
800 (700–1000)
0.931
D-Dimer, µg/L FEU
888 (572–2101)
1056 (544–1632)
0.922
CRP, mg/L
85 (42–127)
110 (85–215)
0.060
Creatinine, mg/dL
0.8 (0.7–1.0)
0.9 (0.8–1.6)
0.091
BUN, mg/dL
38 (28–53)
52 (34–70)
0.093
Glasgow coma scale
15 (15–15)
15 (14.5–15)
0.067
SOFA
2 (2–3)
3 (2–4.5)
0.204
Respiratory rate, bpm
24 (22–29)
26 (24–33)
0.275
PaO2/FiO2, mmHg
194 (122–273)
140 (86.7–281.0)
0.604
A-a O2 gradient, mmHg
204 (69–325)
242 (66–336)
0.960
pH
7.48 (0.05)
7.49 (0.05)
0.389
PaCO2, mmHg
36 (7)
35 (9)
0.598
ROX index
7.6 (4.8–14.5)
8.1 (4.3–16.3)
0.889
Clinical status the day of weaning trial
D-Dimer, µg/L FEU
899 (545–1425)
1244 (845–1375)
0.183
CRP, mg/L
36 (9–59)
70 (18–115)
0.085
SOFA
2 (1.5 – 3)
3 (3–4)
0.003
GCS
15 (15–15)
15 (15–15)
0.423
A-a O2 gradient, mmHg
208 (151–269)
245 (206–445)
0.010
PaO2/FiO2, mmHg
243 (98)
171 (56)
0.014
Respiratory rate, bpm
20 (18–22)
24 (22–27)
< 0.001
pH
7.45 (7.42–7.47)
7.44 (7.42–7.48)
0.638
PaCO2, mmHg
42 (6)
41 (6)
0.653
ROX index
9 (8–11)
7.4 (4.1–8.5)
0.002
mROX index, mmHg/bpm
11.9 (8.5–14.3)
6.6 (5.6–8.8)
< 0.001
Parametric and nonparametric quantitative variables are described with means (standard deviations, SD) and medians (interquartile ranges, IQR), respectively. Chi-squared or Fisher exact test were used to compare qualitative variables, whereas Student t test or Mann–Whitney were used to compare quantitative variables with normal or non-normal distribution, respectively, in patients that failed or succeeded the weaning trial
A-a O2 gradient = alveolar-arterial oxygen gradient; BUN = blood urea nitrogen; CPAP = continuous positive airway pressure; CRP = C reactive protein (upper limit of normal 10 mg/L); FEU = fibrinogen equivalent units; GCS = Glasgow Coma Scale; LMWH = low molecular weight heparin; PaO2 = arterial partial pressure of oxygen; PaCO2 = arterial partial pressure of carbon dioxide; ROX index = SpO2/FiO2/respiratory rate; mROX index = PaO2/FiO2/respiratory rate; SOFA = Sequential Organ Failure Assessment
Fig. 1
Accuracy and performance of predictors of weaning success from helmet CPAP. Receiver operating characteristic (ROC) curves with areas under the ROC curves showing the performance for each index in predicting weaning success (upper panel). Sensitivity and specificity for each weaning predictor is also reported. The left lower panel shows the performance of the mROX threshold of 8.4 mmHg/bpm in predicting weaning outcome in the validation cohort. The right lower panel illustrates the probability to remain on CPAP during the hospital stay in the pooled population (n = 118) in patients with a mROX index of ≥ or < 8.4. CPAP = continuous positive expiratory pressure
×
Anzeige
Our data demonstrated that the mROX index, combining non-invasive surrogates of respiratory distress (RR) and gas exchange efficiency (PaO2/FiO2), was the best predictor of weaning success from CPAP. We observed a relatively low rate of weaning failure, suggesting that weaning attempts tend to be performed late, and reflecting the need for objective and sensitive indicators of weaning preparedness, as for invasive mechanical ventilation [5].
Some limitations need further exploration. First, these thresholds should be tested in randomized clinical trials and compared with standard of care. Second, predictors should be sequentially measured at different time-points during zero-PEEP, to assess their performance variability during the weaning trial and unassisted breathing [2, 6].
In conclusion, the mROX threshold of 8.4 mmHg/bpm appears a sensitive and robust predictor of weaning success from helmet CPAP in patients with COVID-19.
Acknowledgements
The Authors wish to thank all the patients and the healthcare personnel involved in the study and during the COVID-19 pandemic.
Declarations
Ethics approval and consent to participate
The study (ClinicalTrials.gov: NCT04307459) was designed following the amended Declaration of Helsinki (2013), was approved by the local ethical committee (Comitato Etico Area I: 17263/2020) and all patients gave written informed consent.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.
Der optimale Ansatz für die Blutdruckkontrolle bei Patientinnen und Patienten mit akutem Schlaganfall ist noch nicht gefunden. Ob sich eine frühzeitige Therapie der Hypertonie noch während des Transports in die Klinik lohnt, hat jetzt eine Studie aus China untersucht.
Zwar scheint es laut einer Studie aus den USA und Kanada bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.
Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.
Update AINS
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
